LUND, Sweden--(BUSINESS WIRE)--Regulatory News:
BioInvent International AB (OMXS: BINV)
At BioInvent’s Annual General Meeting on 26 March, CEO Svein Mathisen informed the shareholders about the Company´s progress. His presentation concluded that the advances of the clinical portfolio in 2011 will lead to a decisive 2012 with readouts from at least three of the four existing clinical programs. The AGM resolved in accordance with the Board's proposals to amend the provision in the articles of association regarding the auditor’s term and authorize the Board of Directors to issue new shares.
BioInvent International AB (OMXS: BINV)
At BioInvent’s Annual General Meeting on 26 March, CEO Svein Mathisen informed the shareholders about the Company´s progress. His presentation concluded that the advances of the clinical portfolio in 2011 will lead to a decisive 2012 with readouts from at least three of the four existing clinical programs. The AGM resolved in accordance with the Board's proposals to amend the provision in the articles of association regarding the auditor’s term and authorize the Board of Directors to issue new shares.
